Momenta Pharmaceuticals, Inc. (MNTA)

[pollyvonwog]

TEVA filed a CP on 12-31 requesting that FDA refrain from approving any new multiple sclerosis drugs prior to review by an advisory committee in light of the safety issues seen in Tysabri and Gilenya after each were approved and on the market.

Teva highlights Biogen's BG-12 and a potential kidney risk based on information that Biogen posted on a public website.